Funding for this research was provided by:
Conquer Cancer Foundation (NA)
Georgetown University (NA)
Received: 5 July 2019
Accepted: 2 October 2019
First Online: 17 December 2019
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board of Georgetown University (2017–0559. The IRB waived the requirement to obtain informed consent.
: Not applicable.
: Dr. Liu has served as advisory board member/consultant for Apollomics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech/Roche, Heron, Ignyta, Inivata, Janssen, Lilly, Merck, Pfizer, Regeneron, Taiho (DSMB), Takeda/Ariad, and Tempus. Dr. Liu has received research grant (to institution) from AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Clovis, Corvus, Esanex, Genentech/Roche, Ignyta, Lilly, Lycera, Merck, Molecular Partners, OncoMed, Pfizer, Rain Therapeutics, and. Threshold.Dr. Atkins has served as advisory board member for BMS, Merck, Novartis, Arrowhead, Pfizer, Galactone, Werewolf, Fathom, Pneuma, and Leads. Dr. Atkins has served as consultant for BMS, Merck, Novartis, Pfizer, Genentech-Roche, Exelixis, Eisai, Aveo, Array, AstraZeneca, Ideera, Aduro, ImmunoCore, Boehringer-Ingelheim, Iovance, Newlink, Surface, Alexion, Acceleron, Lynx, Cota, and Amgen. Dr. Atkins has received research grant (to institution) from BMS, Merck, Pfizer, and Genentech and owns stock in Werewolf and Pyxis Oncology.Dr. He has served as Speakers Bureau for Bayer, BMS, Eisai, Exili. Dr. He has received research grant (to institution) from Merck.Dr. Kim receives research grant (to institution) from AstraZeneca, BMS, Novartis, Tesaro, Karyopharm.All remaining authors have declared no conflicts of interest.